NIH PAR · NCCIH · R61, R33
PAR-25-269: NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and…
- NOFO number
- PAR-25-269
- Type
- PAR
- Activity code
- R61R33
- Primary institute
- NCCIH · National Center for Complementary and Integrative Health
- Clinical trials
- Required
- Posted
- Dec 2, 2024
- Opens
- May 23, 2025
- Expires
- Nov 14, 2026
PAR-25-269 due dates
1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| June 23, 2025 | June 23, 2025 | July 17, 2025 | November 2025 | January 2026 | April 2026 |
| February 23, 2026 | February 23, 2026 | March 17, 2026 | July 2026 | October 2026 | December 2026 |
| October 20, 2026 | October 20, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
Projects funded under PAR-25-269
NIH RePORTER lists 1 project funded under PAR-25-269 in FY2022–FY2026, with $586K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
1
Distinct projects, FY2022–FY2026
New awards
1
Type 1 (new project) award records
NIH funding
$586K
Award dollars under PAR-25-269, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 1 | 1 | $586K |
Institutions with the most funding
- Yale University$586K · 1 project
Funding institutes
- NCCIH$586K · 1
Activity codes funded
- R611 record
Most recent new awards
- Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes (opens NIH RePORTER)
Yale University · 1R61AT013404-01A1 · NCCIH · Notice Sep 16, 2026
$586KR61
What its predecessor PAR-24-124 funded
PAR-25-269 reissues PAR-24-124. Its funding history is the best guide to who wins under this program: 2 projects and $2.9M in FY2022–FY2026.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$2.9M
Award dollars under PAR-24-124, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 2 | 2 | $2.9M |
Institutions with the most funding
- McLean Hospital$1.7M · 1 project
- Yale University$1.2M · 1 project
Funding institutes
- NCCIH$2.9M · 2
Activity codes funded
- R612 records
Most recent new awards
- Change in LPS with Inulin Supplementation and its Association with Knee Pain among Older Adults with Osteoarthritis (opens NIH RePORTER)
Yale University · 1R61AT013472-01 · NCCIH · Notice Sep 17, 2026
$1.2MR61
- PAIN: Project Assessing the Mechanisms and Impact of a Novel Cannabinoid Product (opens NIH RePORTER)
McLean Hospital · 1R61AT013127-01A1 · NCCIH · Notice Jul 22, 2026
$1.7MR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-269. Contact the program officer at the institute that fits your research before applying.
- NCCIH · National Center for Complementary and Integrative Health
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 1 NOSI to PAR-25-269; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- The budget is limited to 350,000 direct costs per year in both the R61 and R33 phases. Application budgets need to reflect the actual needs of the proposed project.
- Project period
- The scope of the project should determine the project period for each phase. The maximum period of the combined R61 and R33 phases is 5 years, with up to 3 years for the R61 phase and up to 3 years for the R33 phase. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-124.
- Companion NOFOs: PAR-24-312, PAR-24-313, PAR-25-270, PAR-25-271.
Other open NOFOs for R61, R33
- PAR-25-270NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)NCCIH · next due Oct 20, 2026
- PAR-27-045HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)NCCIH · next due Oct 30, 2026
- PAR-25-449Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)NCCIH · next due Feb 8, 2027
- PAR-28-091Assessing the Feasibility of Incorporating Mechanisms in Multi-site Clinical Trials of Mind and Body Interventions on Whole Person Health Restoration (R33 Clinical Trial Required)NCCIH · next due Feb 16, 2027
- PAR-25-210Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)NCCIH · next due Jun 2, 2027
- PAR-25-211Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)NCCIH · next due Jun 2, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.